Peter Goss Comments on Emerging Appellate Split on Generic Drug Preemption

Peter Goss commented for Law360 on a recent ruling by the New Jersey Supreme Court finding no federal preemption where the generic drug manufacturer’s label for metoclopramide (Reglan) did not match that of the brand.  (“NJ Reglan Ruling Widens Generic Label Preemption Split,” available with subscription here.)  Goss noted that the decision conflicted with Fifth and Sixth […]